One Broadway
14th Floor
Cambridge, MA 02142
United States
857 357 7000
https://www.nuvalent.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 106
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. James R. Porter Ph.D. | CEO, President & Director | 1,05M | S.O. | 1976 |
Prof. Matthew D. Shair Ph.D. | Founder, Head of Scientific Advisory Board & Director | 239k | S.O. | 1969 |
Ms. Alexandra Balcom CPA, M.B.A. | CFO & Treasurer | 689,41k | S.O. | 1985 |
Dr. Christopher D. Turner M.D. | Chief Medical Officer | 750,97k | S.O. | 1969 |
Dr. Benjamin Lane Ph.D. | Senior Vice President of Technical Operations | S.O. | S.O. | S.O. |
Ms. Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer & Secretary | 595,96k | S.O. | 1976 |
Mr. Matthew Metivier | Senior Vice President of Human Resources | S.O. | S.O. | S.O. |
Ms. Darlene Noci | Chief Development Officer | S.O. | S.O. | 1978 |
Mr. Henry Pelish Ph.D. | Senior Vice President of Drug Discovery | S.O. | S.O. | S.O. |
Mr. John Soglia Ph.D. | Senior Vice President of Translational Development | S.O. | S.O. | S.O. |
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
L’ISS Governance QualityScore de Nuvalent, Inc. en date du 1 juin 2024 est 9. Les scores principaux sont Audit : 6; Société : 5; Droits des actionnaires : 10; Compensation : 9.